A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
Researchers found that diurnal gut microbe fluctuations are disrupted in individuals with type 2 diabetes, leading to a bacterial signature for risk profiling.
Phenotypic clustering identified distinct forms of PCOS with specific gene variants, providing a promising strategy for enhancing the treatment of this syndrome.
A meta-analysis including 1.4 million people from five ancestral groups identified 318 novel variants associated with type 2 diabetes and related vascular outcomes.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
